Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lilla Vizza
Institution:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Observed institution:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
ORCID:
0009-0002-7734-3426
Observed ORCID:
0009-0002-7734-3426
OpenAlex ID:
A5120618529
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study
2025
·
Irene Marini
, Emilio Francesco Giunta
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
5
PDF
Post-VABB Cavity-Targeted Avidin-Pretargeted [90Y]Y-DOTA-Biotin in Nonpalpable Breast Cancer: A Phase I Activity-Escalation Study (ARTHE)
2026
·
Maddalena Sansovini
, Paola Sanna
, et al.
·
Cancers
Combining immune checkpoint inhibition and dendritic cell vaccination in advanced pleural and peritoneal mesothelioma: The phase 1b MESOVAX trial.
2026
·
Laura Ridolfi
, Angelo Delmonte
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
3
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type